Image: Shutterstock
February 14, 2024 09:00 AM EST
Bioregnum

We just had a string of suc­cess­ful biotech IPOs. Now what?

When CG On­col­o­gy’s $CGON IPO hit a few weeks ago, its suc­cess with in­vestors star­tled a wide swathe of biotech watch­ers who …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Trump asks 'very tough hom­bre' Dr. Oz to lead MFN talks

US warns drug­mak­ers against mis­rep­re­sent­ing cost of im­port­ed prod­ucts

End­points 100 biotech sur­vey: Wel­come to the sum­mer of biotech’s dis­con­tent

Ge­of­frey Porges ex­its Schrödinger with CFO swap; A new board seat for As­traZeneca's Pas­cal So­ri­ot

Meet the ‘first sale’ rule: A cus­toms loop­hole phar­ma com­pa­nies could use to ease tar­iff im­pact

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times